Structure based antibody-like peptidomimetics

Pharmaceuticals

Volumn 5, Issue 2, 2012, Pages 209-235

  Murali, Ramachandran ^a,b   Greene, Mark I ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AERP; AHNP; Antibody; CDR; Drug delivery; Her2; Herceptin; Peptidomimetics; Therapeutics; Tumor imaging

Indexed keywords

ANTIVIRUS AGENT; CHIMERIC ANTIBODY; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MONOCLONAL ANTIBODY; NANOCARRIER; PEPTIDOMIMETIC AGENT; STREPTAVIDIN; SYNTHETIC PEPTIDE; TRASTUZUMAB;

ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; COMPLEMENTARITY DETERMINING REGION; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG STRUCTURE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEAVY CHAIN; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOGENICITY; IN VIVO STUDY; LIGHT CHAIN; MOLECULAR IMAGING; MOLECULAR MIMICRY; MOLECULAR PROBE; NONHUMAN; PEPTIDE ANALYSIS; PROTEIN MOTIF; PROTO ONCOGENE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ACTIVITY RELATION;

EID: 84857677627     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph5020209     Document Type: Article

References (185)

1. Buckel, P. Recombinant proteins for therapy. Trends Pharmacol. Sci. 1996, 17, 450-456.
2. An, Z. Monoclonal antibodies-A proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 2010, 1, 319-330.
3. Saragovi, H.U.; Fitzpatrick, D.; Raktabutr, A.; Nakanishi, H.; Kahn, M.; Greene, M.I. Design and synthesis of a mimetic from an antibody complementarity-determining region. Science 1991, 253, 792-795.
4. Vita, C.; Vizzavona, J.; Drakopoulou, E.; Zinn-Justin, S.; Gilquin, B.; Menez, A. Novel miniproteins engineered by the transfer of active sites to small natural scaffolds. Biopolymers 1998, 47, 93-100.
5. Cooper, W.J.; Waters, M.L. Molecular recognition with designed peptides and proteins. Curr. Opin. Chem. Biol. 2005, 9, 627-631.
6. Craik, D.J.; Clark, R.J.; Daly, N.L. Potential therapeutic applications of the cyclotides and related cystine knot mini-proteins. Expert Opin. Investig. Drugs 2007, 16, 595-604.
7. Beck, A.; Reichert, J.M. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 2011, 3, 415-416.
8. Huang, C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr. Opin. Biotechnol. 2009, 20, 692-699.
9. Lofblom, J.; Frejd, F.Y.; Stahl, S. Non-immunoglobulin based protein scaffolds. Curr. Opin. Biotechnol. 2011, 22, 843-848.
10. Bristow, A.F. Recombinant-DNA-derived insulin analogues as potentially useful therapeutic agents. Trends Biotechnol. 1993, 11, 301-305.
11. Johnson, I.S. Human insulin from recombinant DNA technology. Science 1983, 219, 632-637.
12. Berkower, I. The promise and pitfalls of monoclonal antibody therapeutics. Curr. Opin. Biotechnol. 1996, 7, 622-628.
13. Elkins, K.L.; Ennist, D.L.; Winegar, R.K.; Weir, J.P. In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice. Hum. Gene Ther. 1994, 5, 809-820.
14. Hudson, P.J. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 1999, 11, 548-557.
15. Jones, D.R. Design and Synthesis of Nonpeptide Peptidomimetic Enzyme Inhibitors, and Synthesis and Characterization of C60O, the First Buckminsterfullerene Epoxide; Graduate School of Arts and Sciences, University of Pennsylvania: Philadelphia, PA, USA, 1993.
16. Juweid, M.E.; Hajjar, G.; Swayne, L.C.; Sharkey, R.M.; Suleiman, S.; Herskovic, T.; Pereira, M.; Rubin, A.D.; Goldenberg, D.M. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 1999, 85, 1828-1842.
17. McCafferty, J.; Glover, D.R. Engineering therapeutic proteins. Curr. Opin. Struct. Biol. 2000, 10, 417-420.
18. Cho, M.J.; Juliano, R. Macromolecular versus small-molecule therapeutics: Drug discovery, development and clinical considerations. Trends Biotechnol. 1996, 14, 153-158.
19. Dean, J.H.; Cornacoff, J.B.; Barbolt, T.A.; Gossett, K.A.; LaBrie, T. Pre-clinical toxicity of IL-4: A model for studying protein therapeutics. Int. J. Immunopharmacol. 1992, 14, 391-397.
20. Putney, S.D.; Burke, P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 1998, 16, 153-157.
21. Takakura, Y.; Hashida, M. Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic considerations on biodistribution. Pharm. Res. 1996, 13, 820-831.
22. Thomas, J.A. Recent developments and perspectives of biotechnology-derived products. Toxicology 1995, 105, 7-22.
23. Kohler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495-497.
24. Boswell, C.A.; Brechbiel, M.W. Development of radioimmunotherapeutic and diagnostic antibodies: An inside-out view. Nucl. Med. Biol. 2007, 34, 757-778.
25. Stern, M.; Herrmann, R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit. Rev. Oncol. Hematol. 2005, 54, 11-29.
26. Milenic, D.E.; Brechbiel, M.W. Targeting of radio-isotopes for cancer therapy. Cancer Biol. Ther. 2004, 3, 361-370.
27. Gilliland, L.K.; Walsh, L.A.; Frewin, M.R.; Wise, M.P.; Tone, M.; Hale, G.; Kioussis, D.; Waldmann, H. Elimination of the immunogenicity of therapeutic antibodies. J. Immunol. 1999, 162, 3663-3671.
28. Clark, M. Antibody humanization: A case of the 'Emperor's new clothes'? Immunol. Today 2000, 21, 397-402.
29. Niebecker, R.; Kloft, C. Safety of therapeutic monoclonal antibodies. Curr. Drug Saf. 2010, 5, 275-286.
30. Bhogal, N. Immunotoxicity and immunogenicity of biopharmaceuticals: Design concepts and safety assessment. Curr. Drug. Saf. 2010, 5, 293-307.
31. Tramontano, A.; Bianchi, E.; Venturini, S.; Martin, F.; Pessi, A.; Sollazzo, M. The making of the minibody: An engineered beta-protein for the display of conformationally constrained peptides. J. Mol. Recognit. 1994, 7, 9-24.
32. Kim, S.; Pang, H.B.; Kay, M.S. Peptide mimic of the HIV envelope gp120-gp41 interface. J. Mol. Biol. 2008, 376, 786-797.
33. Zhong, H.; Carlson, H.A. Computational studies and peptidomimetic design for the human p53-MDM2 complex. Proteins 2005, 58, 222-234.
34. Casset, F.; Roux, F.; Mouchet, P.; Bes, C.; Chardes, T.; Granier, C.; Mani, J.C.; Pugniere, M.; Laune, D.; Pau, B.; et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem. Biophys. Res. Commun. 2003, 307, 198-205.
35. Cardo-Vila, M.; Arap, W.; Pasqualini, R. αvβ5 Integrin-dependent programmed cell death triggered by a peptide mimic of annexin V. Mol. Cell. 2003, 11, 1151-1162.
36. Bolin, D.R.; Swain, A.L.; Sarabu, R.; Berthel, S.J.; Gillespie, P.; Huby, N.J.S.; Makofske, R.; Orzechowski, L.; Perrotta, A.; Toth, K.; et al. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. J. Med. Chem. 2000, 43, 2135-2148.
37. Fukumoto, T.; Torigoe, N.; Kawabata, S.; Murakami, M.; Uede, T.; Nishi, T.; Ito, Y.; Sugimura, K. Peptide mimics of the CTLA4-binding domain stimulate T-cell proliferation. Nat. Biotechnol. 1998, 16, 267-270.
38. Kay, B.K.; Kurakin, A.V.; Hyde-DeRuyscher, R. From peptides to drugs via phage display. Drug Discov. Today 1998, 3, 370-378.
39. Phalipon, A.; Folgori, A.; Arondel, J.; Sgaramella, G.; Fortugno, P.; Cortese, R.; Sansonetti, P.J.; Felici, F. Peptide mimicry of carbohydrate structures. Res. Immunol. 1998, 149, 75-77.
40. Bruck, C.; Co, M.S.; Slaoui, M.; Gaulton, G.N.; Smith, T.; Fields, B.N.; Mullins, J.I.; Greene, M.I. Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc. Natl. Acad. Sci. USA 1986, 83, 6578-6582.
41. Kieber-Emmons, T.; Murali, R.; Greene, M.I. Therapeutic peptides and peptidomimetics. Curr. Opin. Biotechnol. 1997, 8, 435-441.
42. Murali, R.; Greene, M.I. Structure-based design of immunologically active therapeutic peptides. Immunol. Res. 1998, 17, 163-169.
43. Horie, T.; Shen, Y.; Kajino, K.; Gaubin, M.; Bonomi, G.; Mani, J.C.; Berezov, A.; Piatier-Tonneau, D.; Guardiola, J.; Hillard, B.; et al. Study of disabling T-cell activation and inhibiting T-cell-mediated immunopathology reveals a possible inverse agonist activity of CD4 peptidomimetics. Exp. Mol. Pathol. 2002, 73, 93-103.
44. Williams, W.V.; Kieber-Emmons, T.; VonFeldt, J.; Greene, M.I.; Weiner, D.B. Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. J. Biol. Chem. 1991, 266, 5182-5190.
45. Zhang, X.; Gaubin, M.; Briant, L.; Srikantan, V.; Murali, R.; Saragovi, U.; Weiner, D.; Devaux, C.; Autiero, M.; Piatier-Tonneau, D.; et al. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. Nat. Biotechnol. 1997, 15, 150-154.
46. Zhang, X.; Piatier-Tonneau, D.; Auffray, C.; Murali, R.; Mahapatra, A.; Zhang, F.; Maier, C.C.; Saragovi, H.; Greene, M.I. Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation. Nat. Biotechnol. 1996, 14, 472-475.
47. Berezov, A.; Zhang, H.T.; Greene, M.I.; Murali, R. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: Structure-function analysis. J. Med. Chem. 2001, 44, 2565-2574.
48. HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 2000, 18, 194-198.
49. Ponde, D.E.; Su, Z.; Berezov, A.; Zhang, H.; Alavi, A.; Greene, M.I.; Murali, R. Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. Bioorg. Med. Chem. Lett. 2011, 21, 2550-2553.
50. Bork, P.; Holm, L.; Sander, C. The immunoglobulin fold. Structural classification, sequence patterns and common core. J. Mol. Biol. 1994, 242, 309-320.
51. Halaby, D.M.; Poupon, A.; Mornon, J. The immunoglobulin fold family: Sequence analysis and 3D structure comparisons. Protein Eng. 1999, 12, 563-571.
52. Buljan, M.; Bateman, A. The evolution of protein domain families. Biochem. Soc. Trans. 2009, 37, 751-755.
53. Dermody, T.S.; Kirchner, E.; Guglielmi, K.M.; Stehle, T. Immunoglobulin superfamily virus receptors and the evolution of adaptive immunity. PLoS Pathog. 2009, 5, e1000481.
54. Schrodinger, L.L.C. The PyMOL Molecular Graphics System, Version 1.3r1; Schrodinger LLC: San Diego, CA, USA, 2010.
55. Bernstein, F.C.; Koetzle, T.F.; Williams, G.J.; Meyer, E.E., Jr.; Brice, M.D.; Rodgers, J.R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The protein data bank: A computer-based archival file for macromolecular structures. J. Mol. Biol. 1977, 112, 535-542.
56. MacCallum, R.M.; Martin, A.C.; Thornton, J.M. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol. 1996, 262, 732-745.
57. Chothia, C.; Lesk, A.M.; Tramontano, A.; Levitt, M.; Smith-Gill, S.J.; Air, G.; Sheriff, S.; Padlan, E.A.; Davies, D.; Tulip, W.R.; et al. Conformations of immunoglobulin hypervariable regions. Nature 1989, 342, 877-883.
58. Bhat, T.N.; Bentley, G.A.; Boulot, G.; Greene, M.I.; Tello, D.; Dall'Acqua, W.; Souchon, H.; Schwarz, F.P.; Mariuzza, R.A.; Poljak, R.J. Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc. Natl. Acad. Sci. USA 1994, 91, 1089-1093.
59. Lescar, J.; Pellegrini, M.; Souchon, H.; Tello, D.; Poljak, R.J.; Peterson, N.; Greene, M.; Alzari, P.M. Crystal structure of a cross-reaction complex between Fab F9.13.7 and guinea fowl lysozyme. J. Biol. Chem. 1995, 270, 18067-18076.
60. Rees, A.R.; Staunton, D.; Webster, D.M.; Searle, S.J.; Henry, A.H.; Pedersen, J.T. Antibody design: Beyond the natural limits. Trends Biotechnol. 1994, 12, 199-206.
61. Decanniere, K.; Desmyter, A.; Lauwereys, M.; Ghahroudi, M.A.; Muyldermans, S.; Wyns, L. A single-domain antibody fragment in complex with RNase A: Non-canonical loop structures and nanomolar affinity using two CDR loops. Structure 1999, 7, 361-370.
62. Spinelli, S.; Frenken, L.G.; Hermans, P.; Verrips, T.; Brown, K.; Tegoni, M.; Cambillau, C. Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry 2000, 39, 1217-1222.
63. Kettleborough, C.A.; Saldanha, J.; Heath, V.J.; Morrison, C.J.; Bendig, M.M. Humanization of a mouse monoclonal antibody by CDR-grafting: The importance of framework residues on loop conformation. Protein Eng. 1991, 4, 773-783.
64. Essig, N.Z.; Wood, J.F.; Howard, A.J.; Raag, R.; Whitlow, M. Crystallization of single-chain Fv proteins. J. Mol. Biol. 1993, 234, 897-901.
65. Arndt, K.M.; Muller, K.M.; Pluckthun, A. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry 1998, 37, 12918-12926.
66. Dolezal, O.; Pearce, L.A.; Lawrence, L.J.; McCoy, A.J.; Hudson, P.J.; Kortt, A.A. ScFv multimers of the anti-neuraminidase antibody NC10: Shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. Protein Eng. 2000, 13, 565-574.
67. Holliger, P.; Prospero, T.; Winter, G. "Diabodies": Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 1993, 90, 6444-6448.
68. Kortt, A.A.; Malby, R.L.; Caldwell, J.B.; Gruen, L.C.; Ivancic, N.; Lawrence, M.C.; Howlett, G.J.; Webster, R.G.; Hudson, P.J.; Colman, P.M. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. Eur. J. Biochem. 1994, 221, 151-157.
69. Freund, C.; Ross, A.; Pluckthun, A.; Holak, T.A. Structural and dynamic properties of the Fv fragment and the single-chain Fv fragment of an antibody in solution investigated by heteronuclear three-dimensional NMR spectroscopy. Biochemistry 1994, 33, 3296-3303.
70. Raag, R.; Whitlow, M. Single-chain Fvs. FASEB J. 1995, 9, 73-80.
71. Colcher, D.; Bird, R.; Roselli, M.; Hardman, K.D.; Johnson, S.; Pope, S.; Dodd, S.W.; Pantoliano, M.W.; Milenic, D.E.; Schlom, J. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Cancer Inst. 1990, 82, 1191-1197.
72. Huston, J.S.; McCartney, J.; Tai, M.S.; Mottola-Hartshorn, C.; Jin, D.; Warren, F.; Keck, P.; Oppermann, H. Medical applications of single-chain antibodies. Int. Rev. Immunol. 1993, 10, 195-217.
73. Yokota, T.; Milenic, D.E.; Whitlow, M.; Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992, 52, 3402-3408.
74. Olafsen, T.; Wu, A.M. Antibody vectors for imaging. Semin. Nucl. Med. 2010, 40, 167-181.
75. Rahbarizadeh, F.; Ahmadvand, D.; Sharifzadeh, Z. Nanobody; an old concept and new vehicle for immunotargeting. Immunol. Invest. 2011, 40, 299-338.
76. Kontermann, R.E. Alternative antibody formats. Curr. Opin. Mol. Ther. 2010, 12, 176-183.
77. Mabry, R.; Snavely, M. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles. IDrugs 2010, 13, 543-549.
78. Thakur, A.; Lum, L.G. Cancer therapy with bispecific antibodies: Clinical experience. Curr. Opin. Mol. Ther. 2010, 12, 340-349.
79. Nelson, A.L. Antibody fragments: Hope and hype. MAbs 2010, 2, 77-83.
80. Balzar, M.; Winter, M.J.; de Boer, C.J.; Litvinov, S.V. The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. 1999, 77, 699-712.
81. Fye, K.H. New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs. Postgrad. Med. 1999, 106, 82-85.
82. Hudson, P.J. Recombinant antibody fragments. Curr. Opin. Biotechnol. 1998, 9, 395-402.
83. Waldmann, T.A. Monoclonal antibodies in diagnosis and therapy. Science 1991, 252, 1657-1662.
84. Attanasio, R.; Kennedy, R.C.; Allan, J.S.; Maino, V.C.; Buck, D.; Kanda, P. Anti-idiotypic antibodies of a predefined specificity generated against CDR3VH synthetic peptides define a private anti-CD4 idiotype. Mol. Immunol. 1990, 27, 513-522.
85. Schroff, R.W.; Foon, K.A.; Beatty, S.M.; Oldham, R.K.; Morgan, A.C., Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 1985, 45, 879-885.
86. Shawler, D.L.; Bartholomew, R.M.; Smith, L.M.; Dillman, R.O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 1985, 135, 1530-1535.
87. Roguska, M.A.; Pedersen, J.T.; Henry, A.H.; Searle, S.M.; Roja, C.M.; Avery, B.; Hoffee, M.; Cook, S.; Lambert, J.M.; Blattler, W.A.; et al. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. Protein Eng. 1996, 9, 895-904; Erratum: Protein Eng. 1997, 10, 181
88. Hamilton, R.G. Monoclonal antibodies in the diagnosis and treatment of human diseases. Ann. Biol. Clin. (Paris) 1989, 47, 575-581.
89. Powelson, J.A.; Knowles, R.W.; Delmonico, F.L.; Kawai, T.; Mourad, G.; Preffer, F.K.; Colvin, R.B.; Cosimi, A.B. CDR-grafted OKT4A monoclonal antibody in cynomolgus renal allograft recipients. Transplantation 1994, 57, 788-793.
90. Winter, G.; Milstein, C. Man-made antibodies. Nature 1991, 349, 293-299.
91. Roguska, M.A.; Pedersen, J.T.; Keddy, C.A.; Henry, A.H.; Searle, S.J.; Lambert, J.M.; Goldmacher, V.S.; Blattler, W.A.; Rees, A.R.; Guild, B.C. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA 1994, 91, 969-973.
92. Almagro, J.C.; Fransson, J. Humanization of antibodies. Front. Biosci. 2008, 13, 1619-1633.
93. King, D.J.; Turner, A.; Farnsworth, A.P.; Adair, J.R.; Owens, R.J.; Pedley, R.B.; Baldock, D.; Proudfoot, K.A.; Lawson, A.D.; Beeley, N.R.; et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 1994, 54, 6176-6185.
94. Coussens, L.; Yang-Feng, T.L.; Liao, Y.C.; Chen, E.; Gray, A.; McGrath, J.; Seeburg, P.H.; Libermann, T.A.; Schlessinger, J.; Francke, U.; et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230, 1132-1139.
95. Nakanishi, H.; Ramurthy, S.; Raktabutr, A.; Shen, R.; Kahn, M. Peptidomimetics of the immunoglobulin supergene family-A review. Gene 1993, 137, 51-56.
96. Moore, G.J. Designing peptide mimetics. Trends Pharmacol. Sci. 1994, 15, 124-129.
97. Vicari, D.; Foy, K.C.; Liotta, E.M.; Kaumaya, P.T. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J. Biol. Chem. 2011, 286, 13612-13625.
98. Eckhardt, B.; Grosse, W.; Essen, L.O.; Geyer, A. Structural characterization of a beta-turn mimic within a protein-protein interface. Proc. Natl. Acad. Sci. USA 2010, 107, 18336-18341.
99. Valadon, P.; Nussbaum, G.; Oh, J.; Scharff, M.D. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide. J. Immunol. 1998, 161, 1829-1836.
100. Wrighton, N.C.; Farrell, F.X.; Chang, R.; Kashyap, A.K.; Barbone, F.P.; Mulcahy, L.S.; Johnson, D.L.; Barrett, R.W.; Jolliffe, L.K.; Dower, W.J. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996, 273, 458-464.
101. Hruby, V.J. Conformational and topographical considerations in the design of biologically active peptides. Biopolymers 1993, 33, 1073-1082.
102. Langston, S. Peptidomimetics and small molecule design. Drug Discov. Today 1997, 2, 254-256.
103. Qabar, M.; Urban, J.; Sia, C.; Klein, M.; Kahn, M. Pharmaceutical applications of peptidomimetics. Lett. Pept. Sci. 1996, 3, 25-30.
104. Hasegawa, A.; Cheng, X.; Kajino, K.; Berezov, A.; Murata, K.; Nakayama, T.; Yagita, H.; Murali, R.; Greene, M.I. Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proc. Natl. Acad. Sci. USA 2004, 101, 6599-6604.
105. Hasegawa, A.; Takasaki, W.; Greene, M.I.; Murali, R. Modifying TNFalpha for therapeutic use: A perspective on the TNF receptor system. Mini. Rev. Med. Chem. 2001, 1, 5-16.
106. Takasaki, W.; Kajino, Y.; Kajino, K.; Murali, R.; Greene, M.I. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor. Nat. Biotechnol. 1997, 15, 1266-1270.
107. Cheng, X.; Kinosaki, M.; Takami, M.; Choi, Y.; Zhang, H.; Murali, R. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J. Biol. Chem. 2004, 279, 8269-8277.
108. Heath, D.J.; Vanderkerken, K.; Cheng, X.; Gallagher, O.; Prideaux, M.; Murali, R.; Croucher, P.I. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 2007, 67, 202-208.
109. Ta, H.M.; Nguyen, G.T.; Jin, H.M.; Choi, J.; Park, H.; Kim, N.; Hwang, H.Y.; Kim, K.K. Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc. Natl. Acad. Sci. USA 2010, 107, 20281-20286.
110. Benkirane, N.; Guichard, G.; Briand, J.P.; Muller, S.; Brown, F.; van Regenmortel, M.H. Mimicry of viral epitopes with retro-inverso peptides of increased stability. Dev. Biol. Stand. 1996, 87, 283-291.
111. de Simone, G.; Lombardi, A.; Galdiero, S.; Nastri, F.; Della Morte, R.; Staiano, N.; Pedone, C.; Bolognesi, M.; Pavone, V. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex. Protein Sci. 1998, 7, 243-253.
112. DeLano, W.L.; Ultsch, M.H.; de Vos, A.M.; Wells, J.A. Convergent solutions to binding at a protein-protein interface. Science 2000, 287, 1279-1283.
113. Kemp, D.S. Peptidomimetics and the template approach to nucleation of beta-sheets and alpha-helices in peptides. Trends Biotechnol. 1990, 8, 249-255.
114. Chen, P.P.; Fong, S.; Normansell, D.; Houghten, R.A.; Karras, J.G.; Vaughan, J.H.; Carson, D.A. Delineation of a cross-reactive idiotype on human autoantibodies with antibody against a synthetic peptide. J. Exp. Med. 1984, 159, 1502-1511.
115. McMillan, S.; Seiden, M.V.; Houghten, R.A.; Clevinger, B.; Davie, J.M.; Lerner, R.A. Synthetic idiotypes: The third hypervariable region of murine anti- dextran antibodies. Cell 1983, 35, 859-863.
116. Meek, K.; Takei, M.; Dang, H.; Sanz, I.; Dauphinee, M.J.; Capra, J.D.; Talal, N. Anti-peptide antibodies detect a lupus-related interspecies idiotype that maps to H chain CDR2. J. Immunol. 1990, 144, 1375-1381.
117. Rini, J.M.; Schulze-Gahmen, U.; Wilson, I.A. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science 1992, 255, 959-965.
118. Tormo, J.; Blaas, D.; Parry, N.R.; Rowlands, D.; Stuart, D.; Fita, I. Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2. EMBO J. 1994, 13, 2247-2256.
119. Fecondo, J.V.; Pavuk, N.C.; Silburn, K.A.; Read, D.M.; Mansell, A.S.; Boyd, A.W.; McPhee, D.A. Synthetic peptide analogs of intercellular adhesion molecule 1 (ICAM-1) inhibit HIV-1 replication in MT-2 cells. AIDS Res. Hum. Retroviruses 1993, 9, 733-740.
120. Tashiro, K.; Nagata, I.; Yamashita, N.; Okazaki, K.; Ogomori, K.; Tashiro, N.; Anai, M. A synthetic peptide deduced from the sequence in the cross-region of laminin A chain mediates neurite outgrowth, cell attachment and heparin binding. Biochem. J. 1994, 302, 73-79.
121. Yayon, A.; Aviezer, D.; Safran, M.; Gross, J.L.; Heldman, Y.; Cabilly, S.; Givol, D.; Katchalski-Katzir, E. Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library. Proc. Natl. Acad. Sci USA 1993, 90, 10643-10647.
122. Balass, M.; Heldman, Y.; Cabilly, S.; Givol, D.; Katchalski-Katzir, E.; Fuchs, S. Identification of a hexapeptide that mimics a conformation-dependent binding site of acetylcholine receptor by use of a phage-epitope library. Proc. Natl. Acad. Sci USA 1993, 90, 10638-10642.
123. Malby, R.L.; Tulip, W.R.; Harley, V.R.; McKimm-Breschkin, J.L.; Laver, W.G.; Webster, R.G.; Colman, P.M. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure 1994, 2, 733-746.
124. Kang, C.Y.; Brunck, T.K.; Kieber-Emmons, T.; Blalock, J.E.; Kohler, H. Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. Science 1988, 240, 1034-1036.
125. Maier, C.C.; LeBoeuf, R.D.; Zhou, S.R.; Whitaker, J.N.; Jarpe, M.A.; Blalock, J.E. The structure of a myelin basic protein-associated idiotope. J. Neuroimmunol. 1993, 46, 235-243.
126. Mazza, G.; Ollier, P.; Somme, G.; Moinier, D.; Rocca-Serra, J.; van Rietschoten, J.; Theze, J.; Fougereau, M. A structural basis for the internal image in the idiotypic network: antibodies against synthetic Ab2-D regions cross-react with the original antigen. Ann. Inst. Pasteur Immunol. 1985, 136D, 259-269.
127. Taub, R.; Gould, R.J.; Garsky, V.M.; Ciccarone, T.M.; Hoxie, J.; Friedman, P.A.; Shattil, S.J. A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen. J. Biol. Chem. 1989, 264, 259-265.
128. Taub, R.; Hsu, J.C.; Garsky, V.M.; Hill, B.L.; Erlanger, B.F.; Kohn, L.D. Peptide sequences from the hypervariable regions of two monoclonal anti-idiotypic antibodies against the thyrotropin (TSH) receptor are similar to TSH and inhibit TSH-increased cAMP production in FRTL-5 thyroid cells. J. Biol. Chem. 1992, 267, 5977-5984.
129. van Cleave, V.H.; Naeve, C.W.; Metzger, D.W. Do antibodies recognize amino acid side chains of protein antigens independently of the carbon backbone? J. Exp. Med. 1988, 167, 1841-1848.
130. Williams, W.V.; Guy, H.R.; Rubin, D.H.; Robey, F.; Myers, J.N.; Kieber-Emmons, T.; Weiner, D.B.; Greene, M.I. Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures. Proc. Natl. Acad. Sci. USA 1988, 85, 6488-6492.
131. Prammer, K.V.; Boyer, J.; Ugen, K.; Shattil, S.J.; Kieber-Emmons, T. Bioactive Arg-Gly-Asp conformations in anti-integrin GPIIb-IIIa antibodies. Receptor 1994, 4, 93-108.
132. Williams, W.V.; London, S.D.; Weiner, D.B.; Wadsworth, S.; Berzofsky, J.A.; Robey, F.; Rubin, D.H.; Greene, M.I. Immune response to a molecularly defined internal image idiotope. J. Immunol. 1989, 142, 4392-4400.
133. Williams, W.V.; Moss, D.A.; Kieber-Emmons, T.; Cohen, J.A.; Myers, J.N.; Weiner, D.B.; Greene, M.I. Development of biologically active peptides based on antibody structure. Proc. Natl. Acad. Sci. USA 1989, 86, 5537-5541.
134. Noseworthy, J.H.; Fields, B.N.; Dichter, M.A.; Sobotka, C.; Pizer, E.; Perry, L.L.; Nepom, J.T.; Greene, M.I. Cell receptors for the mammalian reovirus. I. Syngeneic monoclonal anti- idiotypic antibody identifies a cell surface receptor for reovirus. J. Immunol. 1983, 131, 2533-2538.
135. Co, M.S.; Gaulton, G.N.; Fields, B.N.; Greene, M.I. Isolation and biochemical characterization of the mammalian reovirus type 3 cell-surface receptor. Proc. Natl. Acad. Sci. USA 1985, 82, 1494-1498.
136. Gaulton, G.; Co, M.S.; Greene, M.I. Anti-idiotypic antibody identifies the cellular receptor of reovirus type 3. J. Cell. Biochem. 1985, 28, 69-78.
137. Poljak, R.J.; Amzel, L.M.; Chen, B.L.; Phizackerley, R.P.; Saul, F. Structure and specificity of antibody molecules. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1975, 272, 43-51.
138. Nakajima, H.; Mizuta, N.; Sakaguchi, K.; Fujiwara, I.; Yoshimori, A.; Takahashi, S.; Takasawa, R.; Tanuma, S. Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods. Breast Cancer 2008, 15, 65-72.
139. Nakajima, H.; Mizuta, N.; Sakaguchi, K.; Fujiwara, I.; Yoshimori, A.; Magae, J.; Tanuma, S. Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP. J. Biosci. Bioeng. 2010, 110, 250-253.
140. Murali, R. University of Pennsylvania, Philadelphia, PA, USA. Unpublished work, 2004.
141. Akiyama, T.; Yamada, Y.; Ogawara, H.; Richert, N.; Pastan, I.; Yamamoto, T.; Kasuga, M. Site-specific antibodies to the erbB oncogene product immunoprecipitate epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 1984, 123, 797-802.
142. King, C.R.; Kraus, M.H.; Aaronson, S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985, 229, 974-976.
143. Akiyama, T.; Sudo, C.; Ogawara, H.; Toyoshima, K.; Yamamoto, T. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986, 232, 1644-1646.
144. van de Vijver, M.; van de Bersselaar, R.; Devilee, P.; Cornelisse, C.; Peterse, J.; Nusse, R. Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell. Biol. 1987, 7, 2019-2023.
145. di Fiore, P.P.; Pierce, J.H.; Kraus, M.H.; Segatto, O.; King, C.R.; Aaronson, S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237, 178-182.
146. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
147. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A.; et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
148. Gullick, W.J. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int. J. Cancer Suppl. 1990, 5, 55-61.
149. Maguire, H.C., Jr.; Greene, M.I. Neu (c-erbB-2), a tumor marker in carcinoma of the female breast. Pathobiology 1990, 58, 297-303.
150. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990, 50, 5184-5187.
151. Cohen, J.A.; Weiner, D.B.; More, K.F.; Kokai, Y.; Williams, W.V.; Maguire, H.C., Jr.; LiVolsi, V.A.; Greene, M.I. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 1989, 4, 81-88.
152. Williams, T.M.; Weiner, D.B.; Greene, M.I.; Maguire, H.J. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 1991, 59, 46-52.
153. Drebin, J.A.; Link, V.C.; Stern, D.F.; Weinberg, R.A.; Greene, M.I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985, 41, 697-706.
154. Drebin, J.A.; Link, V.C.; Weinberg, R.A.; Greene, M.I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA 1986, 83, 9129-9133.
155. Drebin, J.A.; Stern, D.F.; Link, V.C.; Weinberg, R.A.; Greene, M.I. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 1984, 312, 545-548.
156. di Fiore, P.P.; Segatto, O.; Aaronson, S.A. Cloning, expression, and biological effects of erbB-2/neu gene in mammalian cells. Meth. Enzymol. 1991, 198, 272-277.
157. Fendly, B.M.; Winget, M.; Hudziak, R.M.; Lipari, M.T.; Napier, M.A.; Ullrich, A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 1990, 50, 1550-1558.
158. Baselga, J.; Norton, L.; Albanell, J.; Kim, Y.M.; Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998, 58, 2825-2831.
159. Carter, P.; Presta, L.; Gorman, C.M.; Ridgway, J.B.; Henner, D.; Wong, W.L.; Rowland, A.M.; Kotts, C.; Carver, M.E.; Shepard, H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 1992, 89, 4285-4289.
160. Hudziak, R.M.; Lewis, G.D.; Winget, M.; Fendly, B.M.; Shepard, H.M.; Ullrich, A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 1989, 9, 1165-1172.
161. her2/neu monoclonal antibodies. Exp. Mol. Pathol. 1999, 67, 15-25.
162. Zhang, X. Structural and functional mapping of immunoglobulin domains. Ph.D. Dissertation, University of Pennsylvania, Philadelphia, PA, 1997.
163. Graciani, N.R.; Tsang, K.Y.; McCutchen, S.L.; Kelly, J.W. Amino acids that specify structure through hydrophobic clustering and histidine-aromatic interactions lead to biologically active peptidomimetics. Bioorg. Med. Chem. 1994, 2, 999-1006.
164. McDonnell, J.M.; Fushman, D.; Cahill, S.M.; Sutton, B.J.; Cowburn, D. Solution structures of Fc epsilon RI alpha-chain mimics: A beta-hairpin peptide and its retroenantiomer. J. Am. Chem. Soc. 1997, 119, 5321-5328.
165. Cho, H.S.; Mason, K.; Ramyar, K.X.; Stanley, A.M.; Gabelli, S.B.; Denney, D.W., Jr.; Leahy, D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421, 756-760.
166. Shepard, H.M.; Lewis, G.D.; Sarup, J.C.; Fendly, B.M.; Maneval, D.; Mordenti, J.; Figari, I.; Kotts, C.E.; Palladino, M.J.; Ullrich, A.; et al. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 1991, 11, 117-127.
167. Sliwkowski, M.X.; Lofgren, J.A.; Lewis, G.D.; Hotaling, T.E.; Fendly, B.M.; Fox, J.A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 1999, 26, 60-70.
168. Baselga, J.; Albanell, J.; Molina, M.A.; Arribas, J. Mechanism of action of trastuzumab and scientific update. Semin. Oncol. 2001, 28, 4-11.
169. Berezov, A.; Chen, J.; Liu, Q.; Zhang, H.T.; Greene, M.I.; Murali, R. Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. 2002, 277, 28330-28339.
170. her2/neu. Oncogene 2006, 25, 7740-7746.
171. Zhang, H.; Cheng, X.; Richter, M.; Greene, M.I. A sensitive and high-throughput assay to detect low-abundance proteins in serum. Nat. Med. 2006, 12, 473-477.
172. Cohen, J.A.; Williams, W.V.; Geller, H.M.; Greene, M.I. Anti-reovirus receptor antibody accelerates expression of the optic nerve oligodendrocyte developmental program. Proc. Natl. Acad. Sci. USA 1991, 88, 1266-1270.
173. Murali, R.; Liu, Q.; Cheng, X.; Berezov, A.; Richter, M.; Furuchi, K.; Greene, M.I.; Zhang, H. Antibody like peptidomimetics as large scale immunodetection probes. Cell. Mol. Biol. (Noisy-le-grand) 2003, 49, 209-216.
174. Teicher, B.A. Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol. Oncol. Clin. North Am. 1995, 9, 475-506.
175. Fantin, V.R.; Berardi, M.J.; Babbe, H.; Michelman, M.V.; Manning, C.M.; Leder, P. A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. Cancer Res. 2005, 65, 6891-6900.
176. Welt, S.; Ritter, G. Antibodies in the therapy of colon cancer. Semin. Oncol. 1999, 26, 683-690.
177. Guillemard, V.; Nedev, H.N.; Berezov, A.; Murali, R.; Saragovi, H.U. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol. 2005, 24, 350-358.
178. Schneider, J.W.; Chang, A.Y.; Garratt, A. Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study. Semin. Oncol. 2002, 29, 22-28.
179. Schneider, J.W. VA Boston Healthcare System and Harvard Medical School, Boston, MA, USA. Personal communicatiion, 2000.
180. Levine, D.H.; Ghoroghchian, P.P.; Freudenberg, J.; Zhang, G.; Therien, M.J.; Greene, M.I.; Hammer, D.A.; Murali, R. Polymersomes: A new multi-functional tool for cancer diagnosis and therapy. Methods 2008, 46, 25-32.
181. Murali, R.; Levine, D.H.; Hammer, D.A. University of Pennsylvania, Philadelphia, PA, USA. Unpublished work, 2008.
182. Afshar, S.; Asai, T.; Morrison, S.L. Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer. Mol. Cancer Ther. 2009, 8, 185-193.
183. Tan, M.; Lan, K.H.; Yao, J.; Lu, C.H.; Sun, M.; Neal, C.L.; Lu, J.; Yu, D. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res. 2006, 66, 3764-3772.
184. Murali, R.; Greene, M. University of Pennsylvania, Philadelphia, PA, USA. Unpublished work, 1999.
185. Wada, T.; Myers, J.N.; Kokai, Y.; Brown, V.I.; Hamuro, J.; LeVea, C.M.; Greene, M.I. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Oncogene 1990, 5, 489-495.